Important pharmacy news and late-breaking industry information updated daily.
The November 2023 deadline for full implementation of the Drug Supply Chain Security Act (DSCSA) looms large, but many of the specifics are far from determined. DSCSA, also known as “track and trace,” mandates that all members of the U.S. supply chain—including pharmacies—use an interoperable electronic system that tracks a drug at the package level until it reaches the pharmacy. The policy is aimed at protecting consumers from counterfeit, stolen, contaminated, or otherwise harmful drugs, including through improved recall processes.
With an increasing number of measles outbreaks across the country and around the world, FDA is stressing its continued confidence in the measles, mumps, and rubella (MMR) vaccine. CDC has reported that outbreaks of mumps have also been reported in the United States this year.
FDA on Friday gave final approval of the first generic naloxone hydrochloride nasal spray (Teva Pharmaceuticals USA). The agency gave tentative approval to this generic drug product in June 2018.
NIH is launching a more than $350 million study that aims to substantially reduce opioid overdose deaths in four states hit hard by the opioid crisis.
Penicillin allergy skin testing (PAST) is rapidly becoming an effective, long-term antimicrobial stewardship tool to optimize antimicrobial prescribing in various practice settings. In February 2019, a group of pharmacists from various institutions across the United States published a practical guide to implementing a PAST program. “Pharmacists are well positioned to offer PAST services given their existing duties as part of the health care team and expertise and training with drug allergy issues,” the authors wrote.
Federal officials announced Wednesday enforcement actions against 60 individuals, including 53 medical professionals, for their alleged participation in the illegal prescribing and distributing of opioids and other dangerous narcotics.
As part of its ongoing efforts to protect consumers from potentially unlawful dietary supplements, FDA said Tuesday it is launching a new tool to quickly alert the public to when it becomes aware of ingredients that appear to be unlawfully marketed in dietary supplements.
The number of confirmed measles cases in the United States increased sharply in the past week, with 90 new cases as of April 11. CDC said Monday there have been 555 cases of the highly infectious disease recorded so far in 2019.
FDA on Friday granted accelerated approval to erdafitinib (Balversa—Janssen Pharmaceutical) for the treatment of adults with locally advanced or metastatic bladder cancer that has an FGFR3 or FGFR2 genetic alteration and that has progressed during or following prior platinum-containing chemotherapy.
FDA issued a final rule on April 11 that would ban certain harmful active ingredients in OTC hand sanitizers. The regulation finalized a previous determination from FDA that 28 active ingredients, including triclosan and benzethonium chloride, are not allowed in these products.